Developmental Therapeutics Core Shared Resource

发育治疗核心共享资源

基本信息

批准号：
10902177
负责人：
Charles David James
金额：
$ 11.32万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-08-15 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10902177
关键词：
3-Dimensional Acceleration Address Adherent Culture Animals Apoptotic Applications Grants Area Biological Biological Assay Cancer Center Cancer Center Support Grant Cancer Model Cancer Patient Cell Line Cellular Assay Client Clinical Trials Comprehensive Cancer Center Consumption Data Developmental Therapeutics Program Drug Formulations Drug Kinetics Drug Stability Engraftment Evaluation Faculty Goals Grant Human IACUC Image Immune response Immune system Immunocompetent Immunologics Immunotherapy In Vitro Invaded Legal patent Libraries Malignant Neoplasms Manuscripts Modeling Modification Molecular Molecular Profiling Mus Operative Surgical Procedures Organoids Patients Peer Review Pharmaceutical Preparations Preclinical Testing Preparation Process Proliferating Protocols documentation Publications Research Research Activity Research Design Research Personnel Resource Sharing Route Services Study models Testing Therapeutic Therapeutic Effect Therapeutic Intervention Time Toxicology Training Translation Initiation Translational Research Treatment Efficacy Tumor Cell Line Xenograft procedure analytical tool cancer subtypes cancer therapy cancer type chemotherapy clinical translation cost discount exome sequencing first-in-human immune system function immunocytochemistry improved in vitro testing in vivo in vivo evaluation interest member migration model development mouse model neoplastic cell novel novel therapeutics operation patient derived xenograft model repository response screening subcutaneous targeted treatment testing services therapeutic candidate therapeutic evaluation three dimensional cell culture transcriptome transcriptome sequencing translational cancer research translational impact treatment effect treatment response tumor tumor growth tumor immunology uptake

3-Dimensional Acceleration Address Adherent Culture Animals Apoptotic Applications Grants Area Biological Biological Assay Cancer Center Cancer Center Support Grant Cancer Model Cancer Patient Cell Line Cellular Assay Client Clinical Trials Comprehensive Cancer Center Consumption Data Developmental Therapeutics Program Drug Formulations Drug Kinetics Drug Stability Engraftment Evaluation Faculty Goals Grant Human IACUC Image Immune response Immune system Immunocompetent Immunologics Immunotherapy In Vitro Invaded Legal patent Libraries Malignant Neoplasms Manuscripts Modeling Modification Molecular Molecular Profiling Mus Operative Surgical Procedures Organoids Patients Peer Review Pharmaceutical Preparations Preclinical Testing Preparation Process Proliferating Protocols documentation Publications Research Research Activity Research Design Research Personnel Resource Sharing Route Services Study models Testing Therapeutic Therapeutic Effect Therapeutic Intervention Time Toxicology Training Translation Initiation Translational Research Treatment Efficacy Tumor Cell Line Xenograft procedure analytical tool cancer subtypes cancer therapy cancer type chemotherapy clinical translation cost discount exome sequencing first-in-human immune system function immunocytochemistry improved in vitro testing in vivo in vivo evaluation interest member migration model development mouse model neoplastic cell novel novel therapeutics operation patient derived xenograft model repository response screening subcutaneous targeted treatment testing services therapeutic candidate therapeutic evaluation three dimensional cell culture transcriptome transcriptome sequencing translational cancer research translational impact treatment effect treatment response tumor tumor growth tumor immunology uptake

展开

项目摘要

ABSTRACT – DEVELOPMENTAL THERAPEUTICS CORE The Developmental Therapeutics Core (DTC) supports LCC investigators in the preclinical testing of novel therapeutics, as well as established agents that are being repurposed, with the primary intent of addressing the merit of advancing novel agents and strategies for clinical trial evaluation. The DTC provides a range of preclinical testing services that include: in vitro tumor cell assays; in vivo subcutaneous and orthotopic models for studying tumor growth, as well as for studying tumor response to therapy; exploratory pharmacokinetics; and exploratory toxicology. The DTC also assists investigators with drug formulations and initial assessments of drug stability. A patient-derived xenograft (PDX) repository provides investigators with more than 60 tumor models representing 12 different types of cancer for in vivo testing of therapies against human tumors. The DTC also maintains a repository with more than 200 human tumor cell lines, many of which can also be used for xenograft establishment and therapeutic testing. DTC staff are proficient in all routes of treatment administration and in small animal surgery, provide consulting and training, and accelerate implementation of studies through simple modification of blanket IACUC protocols. DTC staff advise faculty on study design, and assist with the interpretation and presentation of results for manuscripts and grant applications. The DTC coordinates studies with other LCC shared resources in providing LCC members an integrated and expeditious process for achieving study objectives. During the most recent CCSG grant year the core has had a significant impact on LCC research in aiding 52 Cancer Center members, contributing to publications, and generating results that have helped in obtaining an IND from the FDA for two novel therapeutics that are undergoing clinical trial evaluation in first in human studies. During the current CCSG term, the DTC has assisted LCC members in the preparation of more than 40 grant applications that have resulted in $17M in new external support for LCC research. Experimental results obtained in association with DTC assistance have resulted in 5 patents and 7 applications, and have contributed to the founding of six start-up companies. During the next period of CCSG support, the DTC will continue its robust level of PDX research activity, but will also emphasize the use of syngeneic mouse model tumors for studying immunologic effects of therapy, as well as for testing immunotherapies in animal subjects with an intact, fully functioning immune system.

摘要 - 发育治疗核心发育疗法核心（DTC）支持LCC研究者在新型的临床前测试中治疗以及正在重新使用的既定药物，主要目的是解决推进新型代理和临床试验评估策略的优点。 DTC提供了一系列临床前测试服务，包括：体外肿瘤细胞测定；体内皮下和原位模型用于研究肿瘤生长以及研究肿瘤对治疗的反应；探索性药代动力学；和探索性毒理学。 DTC还协助研究人员进行药物配方和药物的初步评估稳定。患者衍生的异种移植（PDX）存储库为研究人员提供了60多个肿瘤模型代表12种不同类型的癌症，用于对人类肿瘤的疗法进行体内测试。也是DTC 维持具有200多个人类肿瘤细胞系的存储库，其中许多也可以用于异种移植物建立和治疗测试。 DTC员工精通所有治疗途径和小型动物手术，提供咨询和培训，并通过简单地加速研究修改毯子IACUC方案。 DTC的工作人员就研究设计提供了建议，并协助手稿和赠款应用程序结果的解释和呈现。 DTC坐标研究与其他LCC共享资源，为LCC成员提供了一个综合而迅速的过程来实现研究目标。在最近的CCSG赠款年中，核心对LCC研究有重大影响52 癌症中心成员，为出版物做出贡献，并产生有助于获得的结果来自FDA的IND进行了两种新型疗法，这些疗法正在人类研究中进行临床试验评估。在当前的CCSG期限期间，DTC已协助LCC成员准备40多个赠款为LCC研究提供了1700万美元的新外部支持的应用程序。获得的实验结果与DTC援助相关，已获得5项专利和7项申请，并为创立了六家初创公司。在CCSG支持的下一个阶段，DTC将继续其强大 PDX研究活动的水平，但还将强调使用合成小鼠模型肿瘤研究治疗的免疫学作用，以及在具有完整，完全充分的动物受试者中测试免疫疗法功能免疫系统。